Beginning in July, certain Medicare beneficiaries will have access to GLP-1 medications at a set monthly fee. This pilot program aims to run from July 1, 2026, until December 31, 2027. However, questions about its implementation remain just weeks before it launches. The Centers for Medicare and Medicaid Services (CMS) refer to this as a ‘time-limited demonstration’ known as the Medicare GLP-1 Bridge.
Program Details
Eligible Medicare Part D enrollees can receive GLP-1 medications for a $50 monthly copay through this program. Although GLP-1 drugs are typically indicated for diabetes, obesity, and specific heart conditions, this program mainly targets individuals seeking weight management. Beneficiaries who do not qualify for GLP-1 coverage under Part D because of lack of medical necessity will benefit from this initiative. Current federal law does not permit Medicare coverage for weight loss medications.
Organizations like the Obesity Care Advocacy Network (OCAN) have expressed support, with Coordinator Cristy Gallagher recognizing the program as a significant step in combating obesity. Nonetheless, there are concerns regarding the administration and cost of this 18-month program. Questions directed to CMS by journalists, like Bob Herman from Stat News, remain unanswered regarding the program’s financial implications.
How It Works
According to CMS, beneficiaries will not need to complete extra paperwork beyond obtaining a doctor’s prescription. To enroll in the program, a medical provider must issue a prior authorization request, along with a prescription for eligible GLP-1 drugs, such as Wegovy, Zepbound, and Foundayo. If a patient changes medication during the program, a new authorization form is necessary.
Pharmacists will channel prescriptions through a central processor called the Bridge PCN. Aurelia Chaudhury, co-lead of CMS’s Cell and Gene Therapy Access Model, clarified in an OCAN-hosted webinar that prospective prior authorizations won’t be processed. If a patient’s prescription is a first-time GLP-1, the claim is rejected until the authorization is delivered to the provider.
“The Medicare GLP-1 Bridge seeks to test whether providing access to GLP-1 products at a uniform CMS negotiated net price will help improve beneficiary outcomes and reduce long-term Medicare spending,” Kelly Strachan, a CMS insurance specialist, explained.
Eligibility
Beneficiaries need to be part of a standalone prescription drug plan or a Medicare Advantage health plan. Participants can also join through Special Needs Plans, employer/union group waiver plans, or the Limited Income Newly Eligible Transition program. Tricare For Life beneficiaries may participate if they also enroll in an eligible Part D plan. Dual enrollees in both Medicare and Medicaid are included.
Dr. Catherine Varney, an obesity medicine doctor, describes ideal candidates as those most at risk of obesity-related conditions. Eligibility depends on body mass index (BMI) and specific diagnoses, with varying BMI and health criteria specified for the program.
Regulatory Concerns
While the Bridge program sidesteps Medicare’s typical limitations, concerns about potential fraud arise. By extending Medicare access to weight-loss medication prescribers, some observers fear potential misuse. Healthcare regulatory attorney Christopher Frisina noted the possibility of telehealth-related schemes due to inadequate oversight.
Frisina acknowledged CMS’s efforts in setting regulations but warned of potential fraud. “It’s not straightforward like some fraud schemes. Coordination between providers and pharmacies is necessary to facilitate fraud,” he stated. While officials have not detailed the program’s costs, CMS emphasizes this initiative’s unique position outside the usual Part D cost-sharing model.